Marcin Gruchała

ORCID: 0000-0003-4901-2291
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lipoproteins and Cardiovascular Health
  • Cardiac Imaging and Diagnostics
  • Heart Failure Treatment and Management
  • Blood Pressure and Hypertension Studies
  • Heart Rate Variability and Autonomic Control
  • Acute Myocardial Infarction Research
  • Cardiovascular Function and Risk Factors
  • Atrial Fibrillation Management and Outcomes
  • Cancer, Lipids, and Metabolism
  • Coronary Interventions and Diagnostics
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Cardiovascular Health and Disease Prevention
  • Cardiac Valve Diseases and Treatments
  • Cardiovascular Disease and Adiposity
  • Cardiac electrophysiology and arrhythmias
  • Cardiac Health and Mental Health
  • Hormonal Regulation and Hypertension
  • Cardiac Structural Anomalies and Repair
  • Takotsubo Cardiomyopathy and Associated Phenomena
  • Transplantation: Methods and Outcomes
  • Nutrition, Genetics, and Disease
  • Cardiac Arrhythmias and Treatments
  • Cardiac pacing and defibrillation studies
  • Health Systems, Economic Evaluations, Quality of Life
  • Cerebrovascular and Carotid Artery Diseases

Gdańsk Medical University
2016-2025

University Clinical Centre
2019-2022

Gdańsk University of Technology
2022

University of Warmia and Mazury in Olsztyn
2022

Jagiellonian University
2022

University of Opole
2022

Institute of Medical Sciences
2022

European Atherosclerosis Society
2021

Poznan University of Medical Sciences
2020

Foundation of Cardiac Surgery Development
2020

Optimal angiogenic and lymphangiogenic gene therapy requires knowledge of the best growth factors for each purpose. We studied therapeutic potential human vascular endothelial factor (VEGF) family members VEGF-A, VEGF-B, VEGF-C, VEGF-D as well a VEGFR-3–specific mutant (VEGF-C 156S ) using adenoviral transfer in rabbit hindlimb skeletal muscle. The significance proteolytic processing was explored adenoviruses encoding either full-length or mature (ΔNΔC) VEGF-D. Adenoviruses expressing potent...

10.1161/01.res.0000073584.46059.e3 article EN Circulation Research 2003-04-29

It is unclear what the most efficient vector and growth factor for induction of therapeutic vascular in heart. Furthermore, histological nature angiogenesis potential side effects caused by different endothelial factors (VEGFs) myocardium have not been documented.Adenoviruses (Ad) at 2 doses (2x10(11) 2x10(12) viral particles) or naked plasmids (1 mg) encoding LacZ control, VEGF-A165, mature, soluble form VEGF-D (VEGF-D(DeltaNDeltaC)) were injected intramyocardially with NOGA catheter system...

10.1161/01.cir.0000115519.03688.a2 article EN Circulation 2004-02-17

Previous studies have shown that fibroblast growth factor (FGF)-1, FGF-2, and FGF-5 induce therapeutic angiogenesis. Here, we investigated the potential of FGF-4 for neovascularization in comparison to vascular endothelial (VEGF), using adenoviral gene transfer a novel rabbit hind limb ischemia model, with restricted calf. Magnetic resonance imaging modified Miles assay showed both AdFGF-4 AdVEGF given intramuscularly (i.m.) resulted increases permeability edema transduced muscles 6 days...

10.1096/fj.02-0377fje article EN The FASEB Journal 2002-11-15

Inotropes aim at increasing cardiac output by enhancing contractility. They constitute the third pharmacological pillar in treatment of patients with decompensated heart failure, other two being diuretics and vasodilators. Three classes parenterally administered inotropes are currently indicated for (i) beta adrenergic agonists, including dopamine dobutamine also catecholamines epinephrine norepinephrine, (ii) phosphodiesterase III inhibitor milrinone (iii) calcium sensitizer levosimendan....

10.1016/j.ijcard.2019.09.005 article EN cc-by-nc-nd International Journal of Cardiology 2019-09-06

Abstract Aims The coronavirus disease‐2019 (COVID‐19) pandemic has changed the landscape of medical care delivery worldwide. We aimed to assess influence COVID‐19 on hospital admissions and in‐hospital mortality rate in patients with acute heart failure (AHF) a retrospective, multicentre study. Methods results From 1 January 2019 31 December 2020, total 101 433 were hospitalized 24 Cardiology Departments Poland. number admitted due AHF decreased by 23.4% from 9853 7546 2020 ( P < 0.001)....

10.1002/ehf2.13680 article EN cc-by-nc-nd ESC Heart Failure 2021-11-16

Adeno-associated viruses (AAVs) are promising vectors for various gene therapy applications due to their long-lasting transgene expression and wide spectrum of target cells. Recently, however, it has become apparent that there considerable differences in the efficiencies transduction different cell types by AAVs. Here, we analyzed transport mechanisms AAV type 2 (AAV-2) types, emphasizing endothelial Expression analyses both cultured cells rabbit carotid artery assay showed a remarkably low...

10.1128/jvi.76.22.11530-11540.2002 article EN Journal of Virology 2002-10-19

Introduction: Quality of life measures are useful when interventions or treatments indicated for several reasons such as improvement physical functioning, pain relief, to estimate the effectiveness therapies predict mortality.The aim current study was describe quality in patients with stable coronary artery disease, myocardial infarction and heart failure evaluate relationship between depression health-related life.Material methods: Patients after STEMI, (n = 332) completed MacNew Heart...

10.5114/aoms.2014.47881 article EN cc-by-nc-sa Archives of Medical Science 2015-01-28

Abstract Lipoprotein apheresis (LA) is a therapeutic option for hyperlipoproteinemia(a) (hyper-Lp(a)) and atherosclerotic cardiovascular disease (ASCVD). LA improves blood rheology, reduces oxidative stress parameters endothelial function. The underlying molecular mechanisms of beneficial effects are unknown, but it has been suggested that exhibits multiple activities beyond simply removing lipoproteins. We hypothesized removes not only lipoproteins, also extracellular vesicles (EVs). To...

10.1038/s41598-024-51782-5 article EN cc-by Scientific Reports 2024-02-02

Recent discovery of new members the vascular endothelial growth factor (VEGF) family has generated much interest as to which may be best suited for therapeutic angiogenesis in various tissues. In this study we evaluated angiogenic responses different VEGF vivo using adenoviral gene transfer. Adenoviruses (1 × 109 plaque-forming units [pfu]) encoding VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-CΔNΔC and VEGF-DΔNΔC (ΔNΔC are proteolytically cleaved forms) were transferred locally periadventitial...

10.1089/104303403769211664 article EN Human Gene Therapy 2003-09-25

Abstract Background Gene transfer offers considerable potential for altering vessel wall physiology and intervention in vascular disease. Therefore, there is great interest developing optimal strategies vectors efficient, targeted gene delivery into a wall. Methods We studied adeno‐associated viruses (AAV; 9 × 10 8 to 4 TU/ml) their usefulness transduce rabbit arteries vivo comparison with adenoviruses (Adv; 1 pfu/ml). 100 µl of or placebo solution were injected intraluminally transiently...

10.1002/jgm.535 article EN The Journal of Gene Medicine 2004-02-20

The adherence to treatment is defined as the extent which a person’s behavior including taking medication, following diet, and/or executing lifestyle changes, corresponds with agreed recommendations from health care provider. Non-adherence medication may lead increased morbidity, mortality, and costs healthcare system. Therefore it pivotal know true patient's understand causes of low take actions improve adherence. authors assumed that individual, complex education started during...

10.5603/mrj.2017.0016 article EN cc-by-nc-nd Medical Research Journal 2018-03-30

The most reliable care quality indicators for STEMI patients undergoing primary percutaneous coronary intervention (pPCI) include onset-to-door time (OTDT), from admission to wire crossing and in-hospital mortality. Our study aimed evaluate the impact of COVID-19 pandemic on these selected in pre-pandemic groups patients. This single-centre, retrospective study, enrolled 480 patients, aged 63.59 ± 12.44 years treated with pPCI across two frames: (n = 331) 149). evaluation criteria included...

10.3389/fcvm.2025.1522661 article EN cc-by Frontiers in Cardiovascular Medicine 2025-04-16

Adherence to medication is one of the most significant challenges secondary prevention in patients after an acute myocardial infarction (AMI). Indeed, it has been well established that higher adherence associated with better cardiovascular outcomes. Research pertaining AMI treated percutaneous coronary intervention (PCI) focuses mainly on antiplatelet therapy. levels have found be particularly poor and thus, insufficient regards prevention; a high rate discontinuation therapy occurring...

10.5603/cj.a2016.0048 article EN Cardiology Journal 2013-01-02

Diseases of the cardiovascular system and depression are common, they often coexist, significantly deteriorating quality life. Another factor influencing vital functions is impairment cognitive occurring in patients with heart failure (HF). Deficits different degrees severity have been observed within a variety domains. Cognitive deficits, which may impair daily functioning, hinder adaptation to disease worsen prognosis, also depression. The aim this study was assess relationship between...

10.1016/j.ijchp.2016.03.002 article EN cc-by-nc-nd International Journal of Clinical and Health Psychology 2016-05-25

The bicuspid aortic valve (BAV) is commonly associated with the early degeneration of valve. Up to 45% BAV patients over age 50 develop stenosis (AS). Although published data indicate a robust interplay between lipids and calcific AS in tricuspid patients, studies on population are lacking. We aimed evaluate association selected lipid markers occurrence patients. Methods: study included 76 adults (21 female) diagnosed by echocardiography, divided diagnosis. Biochemical parameters...

10.3390/antiox14020167 article EN cc-by Antioxidants 2025-01-30
Coming Soon ...